ALNY vs BNTC
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. BNTC: Benitec Biopharma is a biotechnology company advancing a proprietary 'silence and replace' gene therapy platform to address rare genetic disorders like OPMD.
Side-by-side fundamentals
| Metric | ALNY | BNTC | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $224.53 | $8.75 | |
| Market cap | $30.0B | $305M | |
| P/E as of 2026-10-08 | 38.21 | n/a | |
| Net margin | +8.4% | -23528.8% | ALNY higher |
| Operating margin | +13.5% | -23044.1% | ALNY higher |
| ROE | +39.8% | -25.7% | ALNY higher |
| ROA | +6.3% | -24.9% | ALNY higher |
| Debt / equity as of 2026-09-03 | 2.02 | 0.00 | BNTC lower |
| Revenue growth (YoY) as of 2026-09-03 | +95.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +53.0% | -93.0% | ALNY higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.80 | 0.81 | |
| 1-year return as of 2026-10-08 close | -50.2% | -37.9% | BNTC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.